BI Asset Management Fondsmaeglerselskab A S Reduces Holdings in Halozyme Therapeutics, Inc. $HALO

Key Points

• BI Asset Management cut its Halozyme Therapeutics stake by 39.6% in the first quarter, selling 97,391 shares and leaving it with 148,752 shares worth about $9.6 million.
• Analyst sentiment remains positive, with eight Buy ratings, four Holds, and one Sell; the stock carries a consensus “Moderate Buy” rating and an average price target of $81.60.
• Halozyme’s latest quarterly results beat expectations, posting $1.60 EPS on $376.71 million in revenue, while revenue jumped 42.2% year over year and the company maintained FY2026 EPS guidance of $7.75 to $8.25.

BI Asset Management Fondsmaeglerselskab A S lowered its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 39.6% during the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 148,752 shares of the biopharmaceutical company's stock after selling 97,391 shares during the quarter. BI Asset Management Fondsmaeglerselskab A S owned approximately 0.13% of Halozyme Therapeutics worth $9,614,000 as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of the stock. Clark Capital Management Group Inc. lifted its holdings in Halozyme Therapeutics by 14.4% in the 3rd quarter. Clark Capital Management Group Inc. now owns 202,965 shares of the biopharmaceutical company's stock valued at $14,885,000 after purchasing an additional 25,582 shares in the last quarter. Intech Investment Management LLC lifted its stake in shares of Halozyme Therapeutics by 46.0% during the third quarter. Intech Investment Management LLC now owns 148,667 shares of the biopharmaceutical company's stock valued at $10,903,000 after buying an additional 46,850 shares during the period. Allworth Financial LP boosted its position in Halozyme Therapeutics by 322.5% during the third quarter. Allworth Financial LP now owns 39,736 shares of the biopharmaceutical company's stock worth $2,914,000 after acquiring an additional 30,331 shares during the last quarter. Element Squared LLC purchased a new stake in Halozyme Therapeutics in the 4th quarter worth approximately $1,193,000. Finally, Dimensional Fund Advisors LP raised its holdings in Halozyme Therapeutics by 3.2% in the 3rd quarter. Dimensional Fund Advisors LP now owns 2,078,426 shares of the biopharmaceutical company's stock valued at $152,431,000 after acquiring an additional 63,699 shares during the last quarter. Institutional investors and hedge funds own 97.79% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on HALO shares. Weiss Ratings raised Halozyme Therapeutics from a "hold (c)" rating to a "buy (b-)" rating in a research report on Tuesday, May 12th. Morgan Stanley lowered their price target on Halozyme Therapeutics from $96.00 to $93.00 and set an "overweight" rating for the company in a report on Tuesday, May 12th. UBS Group reaffirmed a "buy" rating and set a $90.00 price objective on shares of Halozyme Therapeutics in a research note on Wednesday, June 3rd. Wall Street Zen upgraded shares of Halozyme Therapeutics from a "hold" rating to a "buy" rating in a report on Saturday, May 16th. Finally, Benchmark reissued a "buy" rating on shares of Halozyme Therapeutics in a research report on Wednesday, June 3rd. Eight investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $81.60.

Insider Activity

In other news, CEO Helen Torley sold 20,000 shares of the company's stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $67.58, for a total value of $1,351,600.00. Following the completion of the sale, the chief executive officer owned 767,780 shares of the company's stock, valued at $51,886,572.40. This represents a 2.54% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,625 shares of the stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $66.21, for a total value of $107,591.25. Following the completion of the sale, the director owned 43,669 shares of the company's stock, valued at approximately $2,891,324.49. This trade represents a 3.59% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 93,250 shares of company stock worth $6,299,746 over the last three months. 2.50% of the stock is currently owned by corporate insiders.

Halozyme Therapeutics Price Performance

Halozyme Therapeutics stock opened at $68.55 on Monday. Halozyme Therapeutics, Inc. has a 52-week low of $51.06 and a 52-week high of $82.22. The firm has a fifty day moving average of $68.02 and a 200-day moving average of $68.64. The firm has a market capitalization of $8.13 billion, a P/E ratio of 24.66, a PEG ratio of 0.28 and a beta of 0.88. The company has a quick ratio of 2.33, a current ratio of 2.76 and a debt-to-equity ratio of 8.81.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share for the quarter, beating the consensus estimate of $1.54 by $0.06. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. The business had revenue of $376.71 million for the quarter, compared to analyst estimates of $358.60 million. During the same quarter in the previous year, the business posted $1.11 EPS. The business's quarterly revenue was up 42.2% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. As a group, analysts predict that Halozyme Therapeutics, Inc. will post 7.54 EPS for the current year.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company's core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company's flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.

Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.